The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 26, 2024
Filed:
Aug. 31, 2018
Applicant:
Northwestern University, Evanston, IL (US);
Inventors:
Gary E. Schiltz, Naperville, IL (US);
Rama K. Mishra, Chicago, IL (US);
Huiying Han, Chicago, IL (US);
Sarki A. Abdulkadir, Lombard, IL (US);
Javier Izquierdo-Ferrer, Chicago, IL (US);
Atul D. Jain, Chicago, IL (US);
Assignee:
Northwestern University, Evanston, IL (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 231/20 (2006.01); A61P 35/00 (2006.01); C07D 231/06 (2006.01); C07D 231/12 (2006.01); C07D 239/26 (2006.01); C07D 239/42 (2006.01); C07D 249/06 (2006.01); C07D 261/08 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 405/04 (2006.01); C07D 405/10 (2006.01); C07D 405/12 (2006.01); C07D 409/10 (2006.01); C07D 498/04 (2006.01);
U.S. Cl.
CPC ...
C07D 231/20 (2013.01); A61P 35/00 (2018.01); C07D 231/06 (2013.01); C07D 231/12 (2013.01); C07D 239/26 (2013.01); C07D 239/42 (2013.01); C07D 249/06 (2013.01); C07D 261/08 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 405/04 (2013.01); C07D 405/10 (2013.01); C07D 405/12 (2013.01); C07D 409/10 (2013.01); C07D 498/04 (2013.01);
Abstract
Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.